OrthoPediatrics Reports Record Q3 2026 Revenue and Raises Full-Year Guidance
OrthoPediatrics (KIDS) reported strong third-quarter results for 2026, with total revenue reaching $72.7 million, a 19% increase year-over-year. Growth was driven by robust demand in the Trauma and Deformity segment ($52.6 million) and Scoliosis segment ($19.2 million). The company achieved record adjusted EBITDA of $6.9 million and successfully returned to positive free cash flow of $1.6 million. Following these results, management raised its full-year revenue guidance to a range of $270 million to $273 million. While the company noted some international growth was tempered by strategic decisions to restrict set sales in certain markets like Brazil to manage accounts receivable, the overall outlook remains positive due to an ongoing 'innovation super cycle' of new pediatric-specific products.
Tickers: $KIDS
Topics: EBITDA Financial Performance Guidance Raise Revenue Growth